Advancing TechBio solutions in regenerative medicine
Established in 2017, CUTISS is a late-stage clinical TechBio company focused on skin tissue therapeutics, regenerative medicine, tissue engineering, and skin pigmentation.
At CUTISS we care
Our mission is to revolutionize skin surgery and advance dermatology through personalized tissue therapies, leveraging cutting-edge automation to ensure scalability, precision, and global patient accessibility.


Our Team
We have a multidisciplinary team of around 50 employees, including world-class senior executives, advisors and investors. Our team consists of scientists, medical doctors, GMP manufacturers, translational researchers and regulatory experts, clinical trial managers, as well as product and business development and industrial experts.
CUTISS Innovation – Advancing R&D in regenerative medicine
Our subsidiary company CUTISS Innovation is based in Sophia Antipolis in France and is dedicated to advancing R&D and next-generation regenerative medicine technologies that can be applied on Earth as well as in space, and beyond medicine.
Management
Dr Daniela Marino is the Co-Founder and CEO of CUTISS AG. Daniela holds a Master in Biotechnology from the University of Milano and a PhD in Sciences from ETH Zurich. With her focus on vascular and stem cell biology, in 2009 she joined the Tissue Biology Research Unit of the University of Zurich as a post doc and project manager, to then transition to a project co-leader and business developer role at the start-up accelerator Wyss Zurich. In 2017, on the back end of the safety readout for denovoSkin™, she co-founded CUTISS AG, to further develop the bio-engineered skin equivalent towards commercialization. Among other recognitions, Daniela was awarded the Female Innovator of the Year in 2019.
Dr. Vincent Ronfard holds Engineering degree and PhD in Biology UT Compiegne in France. As Chief Innovation Officer at Cutiss AG, he manages CUTISS’ R&D and Clinical departments, as well as the French subsidiary CUTISS Innovation. Vincent has more than 35 years of experience in the field of Regenerative Medicine. He worked at Organogenesis Inc., Modex Therapeutics, L'Oreal, HealthPoint, Smith & Nephew, and A*STAR Singapore. He is also co-founder of Hairclone Inc.
In her role as Chief Operating Officer at CUTISS, Kathi oversees the Operations, including the GMP production, the Quality Assurance, the Quality Control and the Regulatory Affairs.
With over 25 years of experience in life sciences and medical research, she has held senior roles at Modex Therapeutics, DFB pharmaceuticals, Healthpoint Biotherapeutics, Smith & Nephew ( (Switzerland and USA) and the Skin Research Institute in Singapore . Kathi has a background in biotechnology, in Management of biotechs and an MBA . With her expertise in translating regenerative medicine products from bench to the bed side, she drives operational excellence in GMP.
Board of Directors

Prof. Dr. med.
Martin Meuli
Co-Founder
Prof. em. Dr. med. Martin Meuli studied medicine at the University of Zurich and is board-certified in Pediatric Surgery. He completed a research fellowship at the University of California San Francisco (1993–1995), focusing on skin wound healing and fetal surgery for congenital malformations, particularly Spina Bifida.
At Kinderspital Zurich, he directed the Pediatric Burn and Reconstructive Surgery Center until 2003 and from then on served as Chairman of the Department of Surgery and as Ordinary Professor at the University of Zurich until 2020. His research pioneered lab-grown, patient-derived skin grafts and human fetal surgery for Spina Bifida in Switzerland (2010).
A Co-Founder of CUTISS, he has chaired its Board since 2017 and serves as a Medical Consultant.

Giammaria
Giuliani
BoD
Giammaria started his professional career in 2002, at Leo Burnett (Publicis Group). Subsequently, in 2004, he assumed the role of Executive Vice-President and Head of R&D at Giuliani SpA.
Since 2014, as a healthcare investor, he has been holding various board positions in pharmaceutical and biotech companies and in this context participates in defining their investment strategy and ensuring that it is aligned with their mission and values. He is also involved in developing and financing medical and scientific research projects. Moreover, Giammaria has extended his influence into philanthropy, through the Giuliani Foundation, focusing on education, health and economic well-being.

Prof. Dr. Ernst
Reichmann
Co-Founder
Prof. em. Dr. Ernst Reichmann is Co-founder and member of the board of CUTISS AG. As a cell biologist, he became director of the Tissue Biology Research Unit (TBRU) in 2001. He introduced collagen type I hydrogels and their plastic compression which both were essential prerequisites for the development of denovoSkin™ in the TBRU.
In addition, he initiated the vascularization and pigmentation of denovoSkin, resulting in likely the most complex bioengineered human skin to date. Ernst Reichmann was able to raise the funds enabling the initial GMP skin manufacturing unit at the UZH and to conduct the first Phase I clinical trials at the Kinderspital Zurich.

Dr. Daniela
Marino
Member of the BoD
Dr Daniela Marino is the Co-Founder and CEO of CUTISS AG. Daniela holds a Master in Biotechnology from the University of Milano and a PhD in Sciences from ETH Zurich. With her focus on vascular and stem cell biology, in 2009 she joined the Tissue Biology Research Unit of the University of Zurich as a post doc and project manager, to then transition to a project co-leader and business developer role at the start-up accelerator Wyss Zurich. In 2017, on the back end of the safety readout for denovoSkin™, she co-founded CUTISS AG, to further develop the bio-engineered skin equivalent towards commercialization. Among other recognitions, Daniela was awarded the Female Innovator of the Year in 2019.

Dr. Gérard
Ber
Member of the BoD
Dr. Gérard Ber has served on the Board of Directors since 2020 and is also a member of Lantheus Inc. A Doctor of Pharmacy by training, he co-founded Advanced Accelerator Applications S.A. and served as Chief Operating Officer until its acquisition by Novartis AG.
With over 30 years of experience in molecular nuclear medicine, he specializes in the development, production, and commercialization of diagnostic and therapeutic products across various diseases.

Dr. Shulamit
Hadi
Member of the BoD
Dr. Shulamit Hadi is a Board Member at CUTISS AG and Founder of Shiloh Advisors AG. With experience across Fortune 500 companies and startups, she advises on strategy, growth, and investments. A frequent speaker at global conferences, she also serves on boards of disruptive companies.
An entrepreneur, investor, and business strategist, Dr. Hadi holds a PhD from Albert-Ludwig University, Germany, with degrees in Sciences, Business, and Education. She founded the “Envelope Project” to support disadvantaged families, reflecting her commitment to social impact.
Key Advisors

Ralf
Rosenow
Secretary to the BoD

Dr. med.
Luc Téot
Medical Officer

Prof. Thierry
Passeron
Vitiligo

Dr. Anke
Ness
CFO

Dr. med. Clemens
Schiestl
and Co-Founder
Our Departments

Clinical
f.l.t.r.: Stella Nuber, Dr. Vincent Ronfard (Head of Department),
Dr. Fabienne Hartmann-Fritsch, Nicole Weiner

Research and Development
f.l.t.r: Dr. Anna-Lena Murphy, Elena Zanini, Dr. Johanna Diener, Giuditta Thoma,
Pablo Marty, Zuzana Oulehlovà, Angela Bucherer, Dr. Laurent Barnes,
Dr. Vincent Ronfard (Head of Department)
front: Luca Vernazza, Hatice Özcan, Thomas Jörimann

GMP Production
f.l.t.r.: Kathi Mujynya (Head of Department), Stella Nuber, Nathalie Moro, Laia Valor, Miralda Salaij, Maria Zappalà, Chiara Pagliuca
front: Christina Georgopoulou, Chiara Solfi, Patrick Urech, Janine Meier

Quality Assurance
f.l.t.r.: Dr. Patrick Buschor, Kathi Mujynya (Head of Department), Dr. Darjan Andrejc, Brenda Serafim, Léa Philippe, Matteo Scaltritti

Quality Control
f.l.t.r.: Belén Cantó Martorell, Alessandro Fiscalini, Robert Pritchard, Dr. Joaquin Urdinez, Kathi Mujynya (Head of Department)
front: Jovita Kobler, Lisa Sannitz, Alexandra Hugo, Veronica Bösiger

Regulatory Affairs
f.l.t.r.: Arina Löw, Kathi Mujynya (Head of Department), Chiara Solfi

Administration and Finance
f.l.t.r.: Jackie Vuistiner, Anne Wainaina, Dr. Daniela Marino (Head of Department), Sandra Wong-Brawand, Dr. Anke Ness, missing: Adeline Beaupoil

CUTISS Innovation
f.l.t.r.: Christophe Zimmer, Andreea Iordan, Cécile Cousin, Dr. Vincent Ronfard (Head of Department), Yaël Berton, Clarisse Broguet
From idea to impact: How CUTISS was founded
In early 2001, a visionary team at the University of Zurich (UZH) set out to transform skin surgery.
Urs Stauffer—Director of the Surgical Clinic at the University Children’s Hospital in Zurich (KISPI)—Martin Meuli, successor of Urs Stauffer, and cell biologist Ernst Reichmann established the Tissue Biology Research Unit (TBRU). Reichmann, in these days the Director of the TBRU, introduced the idea of growing human skin cells in and on plastically compressed collagen hydrogel, a material that closely mirrors the cells natural extracellular environment. The result was denovoSkin, a promising skin substitute.
Under Reichmann’s leadership the project progressed at TBRU with a dedicated research team including among others researchers Daniela Marino and Fabienne Hartmann-Fritsch. DenovoSkin’s clinical application benefited a lot from the medical and clinical input and collaboration of Martin Meuli and Clemens Schiestl, in these days Directors of the Pediatric Burn Center at KISPI Zurich.
In 2011, thanks to a large EU cooperation grant, TBRU began its translational research phase with the GMP (Good Manufacturing Practice) production and clinical application of denovoSkin™. Between 2014 and 2016, ten paediatric patients were enrolled and transplanted by pioneer surgeons Martin Meuli and Clemens Schiestl in the world’s first Phase I clinical trial at KISPI. With very promising preliminary clinical data, Daniela Marino and Ernst Reichmann developed a first business plan supported by Innosuisse, the Swiss Innovation Agency. Soon, the project earned notable recognition by winning the Swiss Venture Award in 2015, affirming its innovative potential and grand mission: Taking denovoSkin™ to market.
In 2016, the denovoSkin™ project was accelerated by the start-up incubator Wyss Zurich, and in 2017 CUTISS AG was incorporated by the founding quintet: Daniela, Fabienne, Ernst, Martin and Clemens.
We remain deeply thankful to Wyss Zurich and all our early supporters, including Fondation Gaydoul, Thérèse Meier, Fondation Sana, Vontobel Stiftung, and many others, whose invaluable contributions were instrumental from the very beginning.
The Founding Team

from left to right PD Dr. med. Clemens Schiestl, Prof. Dr. Ernst Reichmann, Prof. Dr. med. Martin Meuli, Dr. sc. Daniela Marino, Dr. sc. nat. Fabienne Hartmann-Fritsch